載入中
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
前收盤價
US$16.64
+US$0.27 · +1.65%
盤中時間採用ET。市場資料可能有所延遲。
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
日內區間
目前US$16.64
52週區間
目前US$16.64
盤中時間採用ET。市場資料可能有所延遲。
Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.
日內區間
目前US$16.64
52週區間
目前US$16.64
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 204.9萬 USD | 224.3萬 USD | 246.1萬 USD | — | — |
| 毛利 | −204.9萬 USD | −224.3萬 USD | −246.1萬 USD | — | — |
| 研究與開發 | 3.98億 USD | 2.81億 USD | 2.11億 USD | 1.43億 USD | 1.21億 USD |
| 銷售、一般及管理費用 | 6985.1萬 USD | 6248萬 USD | 3140萬 USD | 2820.2萬 USD | 2871.7萬 USD |
| 營業費用 | 4.66億 USD | 3.42億 USD | 2.4億 USD | 1.71億 USD | 1.5億 USD |
| 利息收入 | 2985.9萬 USD | 2692.2萬 USD | 764.1萬 USD | 291.7萬 USD | 74.2萬 USD |
| 利息支出 | 619.2萬 USD | — | — | 291.7萬 USD | — |
| 折舊和攤銷 | 204.9萬 USD | 167.3萬 USD | 167.3萬 USD | 168.3萬 USD | 108.8萬 USD |
| 營業利益 | −4.68億 USD | −3.44億 USD | −2.42億 USD | −1.71億 USD | −1.5億 USD |
| 淨利 | −4.46億 USD | −3.17億 USD | −2.36億 USD | −1.68億 USD | −1.49億 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.34億0.01%2.3兆 USD0.03%US$381.94+0.63%
State Street SPDR S&P Biotech ETFXBI7216.69萬0.73%98.74億 USD0.35%US$153.77+3.00%
iShares Russell 2000 ETFIWM6634.73萬0.08%787.4億 USD0.19%US$278.94+0.49%
Vanguard Extended Market ETFVXF4886.76萬0.05%954億 USD0.05%US$235+0.80%
Vanguard Morningstar Small-Cap ETFVB4831.19萬0.03%1853億 USD0.03%US$289.48+0.64%
Vanguard Morningstar Small-Cap Value ETFVBR3070.29萬0.04%682億 USD0.05%US$234.43+0.22%
Vanguard Russell 2000 ETFVTWO2214.79萬0.12%180億 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB1945.47萬0.18%108.2億 USD0.44%US$206.49+3.00%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Morningstar Small-Cap ETFVBVanguard Morningstar Small-Cap Value ETFVBRVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
